Звяглова Мария Юрьевна
Moscow Clinical Scientific Center · 36 works · 53 citations · h-index 4
Top works
- Pharmacological and clinical feature of rebamipide: new therapeutic targets
- Enteropathy with impaired membrane digestion and rebamipide
- Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
- Enteropathy with impaired membrane digestion as nosological form
- Thromboembolic complications in patients with inflammatory bowel diseases
- Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation
- P476 Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis
- P007 The Frequency of Anxiety and Depression in Patients With Inflammatory Bowel Diseases in the Moscow Clinical Scientific Center
- DOP77 The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease
- P243 Elevated presepsin levels are a marker of sepsis risk in patients with inflammatory bowel diseases receiving therapy of TNF-α blockers
- P017 Increased Level of Immunoglobulin G in the Development of Adverse Reactions in Patients With Ulcerative Colitis
- Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation
- S33 Alpha-1 Antitrypsin is a Marker of Increased Intestinal Permeability in Ulcerative Colitis and COVID-19 Infection
- Stem Cell Therapy for Perianal Crohn’s Disease
- P270 Mesenchymal stromal cells contribute to the recovery of secondary loss of response to infliximab in patients with ulcerative colitis
- Efficacy and safety of ustekinumab in patients with Crohn’s disease in real clinical practice
- ФАРМАКОЛОГИЧЕСКИЙ И КЛИНИЧЕСКИЙ ПРОФИЛЬ РЕБАМИПИДА: НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ МИШЕНИ
- Эффективность препарата устекинумаб у пациента с язвенным колитом после неудачи терапии блокаторами ФНО-альфа, блокатором янус-киназ и ингибитором альфа-4-бета-7-интегрина
- P004 Combined Biological Therapy of Perianal Crohn's Disease
- Энтеропатия с нарушением мембранного пищеварения и ребамипид